Ruili Huang

national institutes of health (nih) - usa

H指数:58

被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

In vitro bioactivity profile-driven discovery of drug synergies in hepatocellular carcinoma

基于体外生物活性谱驱动的肝细胞癌药物协同作用发现

Journal of Translational Medicine

IF7.5

2026-07-280

Analysis of in vitro profiling data of cosmetic ingredients within the Tox21 10K compound library for bioactivity and potential toxicity

在Tox21 10K化合物库中对化妆品成分的体外表征数据进行生物活性和潜在毒性分析

BMC Pharmacology & Toxicology

IF2.7

2026-06-160

Impact of Chemical Quality on High-Throughput in Vitro Assays: A Tox21 Study

化学质量对高通量体外实验的影响：一项Tox21研究

Chemical Research in Toxicology

IF3.8

2026-04-090

PRE

Expanded Tox21 Biological Assay Panel for the Prediction of Drug-Induced Liver Injury and Cardiotoxicity

扩展的Tox21生物检测面板用于预测药物诱导的肝损伤和心脏毒性

Environmental Health Perspectives

IF9.8

2026-04-010

OAAI

Identifying androgen receptor antagonists using a metabolically competent high-throughput screening assay

使用具有代谢能力的快速筛选方法鉴定雄激素受体拮抗剂

Current Research in Toxicology

IF3

2025-12-190

OAAI

Systematic evaluation of Tox21 compounds that target β-adrenergic receptors and their role in cardiotoxicity

对靶向β-肾上腺素能受体的Tox21化合物的系统评价及其在心脏毒性中的作用

Toxicology and Applied Pharmacology

IF3.4

2025-09-140

PREAI

MT1G activation in dopaminergic neurons identifies chelators and their relationships to cytotoxicity

MT1G在多巴胺能神经元中的激活鉴定了螯合剂及其与细胞毒性的关系

SLAS Discovery

IF2.7

2025-07-030

OAAI

Leveraging viral genome sequences and machine learning models for identification of potentially selective antiviral agents

利用病毒基因组序列和机器学习模型识别潜在的选择性抗病毒剂

Communications Chemistry

IF6.2

2025-06-200

OAAI

Application of cytochrome P450 enzyme assays to predict p53 inducers and AChE inhibitors that require metabolic activation

TOXICOLOGY AND APPLIED PHARMACOLOGY

IF3.4

2025-04-010

PRE

Investigating blood-brain barrier penetration and neurotoxicity of natural products for central nervous system drug development

SCIENTIFIC REPORTS

IF3.9

2025-03-030

OAAI

Lessons learned from evaluating defined chemical mixtures in a high-throughput estrogen receptor assay system

TOXICOLOGICAL SCIENCES

IF4.1

2025-02-200

PRE

Systematic identification of cancer pathways and potential drugs for intervention through multi-omics analysis

通过多组学分析系统性地识别癌症通路及干预的潜在药物

PHARMACOGENOMICS JOURNAL

IF2.9

2025-02-190

Genetic Variants of GBP4: Reduced Risks for Drug-Induced Acute Liver Failure in Non-Finnish European Population

GBP4的遗传变异: 降低非芬兰欧洲人群药物诱导的急性肝衰竭的风险

LIVER INTERNATIONAL

IF5.2

2025-01-270

PRE

Analytical Quality Evaluation of the Tox21 Compound Library

Tox21化合物库的分析质量评价

CHEMICAL RESEARCH IN TOXICOLOGY

IF3.8

2024-12-311

OAAI

Prediction of chemical-induced acute toxicity using in vitro assay data and chemical structure

使用体外测定数据和化学结构预测化学诱导的急性毒性

TOXICOLOGY AND APPLIED PHARMACOLOGY

IF3.4

2024-11-011

PRE

Evaluating the Utility of the MSTI Assay in Predicting Compound Promiscuity and Cytotoxicity

CHEMICAL RESEARCH IN TOXICOLOGY

IF3.8

2024-09-100

PRE

Identification of Environmental Compounds That May Trigger Early Female Puberty by Activating Human GnRHR and KISS1R

ENDOCRINOLOGY

IF3.3

2024-09-100

PRE

Use of Tox21 screening data to profile PFAS bioactivities on nuclear receptors, cellular stress pathways, and cytochrome p450 enzymes

JOURNAL OF HAZARDOUS MATERIALS

IF11.3

2024-07-011

OAAI

Decoding the κ Opioid Receptor (KOR): Advancements in Structural Understanding and Implications for Opioid Analgesic Development

MOLECULES

IF4.6

2024-06-030

OAAI

NAD activates olfactory receptor 1386 to regulate type I interferon responses in Plasmodium yoelii YM infection

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2024-05-290

OAAI

Ruili Huang

个人简介

教育背景

工作经历

荣誉奖项

研究方向